What are the adverse reactions of Tisotumab vedotin-tftv?

Vedotin-Tisotumab vedotin-tftv is a tissue factor-directed antibody-drug conjugate indicated for the treatment of adult patients with recurrent or metastatic cervical cancer who have experienced disease progression during or after chemotherapy.

In clinical studies of Vitin-tisotuzumab, the most common (≥25%) adverse reactions (including laboratory abnormalities) include decreased hemoglobin, fatigue, lymphopenia, nausea, peripheral neuropathy, alopecia, epistaxis, conjunctival adverse reactions, bleeding, leukopenia, and increased creatinine , dry eye, increased prothrombin international normalized ratio, prolonged activated partial thromboplastin time, diarrhea and rash; the most common (≥3%) serious adverse reactions are intestinal obstruction, bleeding, pneumonia, peripheral neuropathy, sepsis, constipation and pyrexia; fatal adverse reactions include septic shock, pneumonia, sudden death and multisystem organ failure.

Adverse reactions leading to dose reduction occurred in 23% of patients, and the most common (≥3%) adverse reactions were conjunctival adverse reactions and corneal adverse reactions; 47% of patients experienced adverse reactions leading to dose interruption, including peripheral neuropathy, conjunctival adverse reactions, and bleeding; 13% of patients experienced adverse reactions leading to permanent discontinuation, including peripheral neuropathy and corneal adverse reactions.

Vitin-TisotumabThe original drug has not yet been marketed in China, so it cannot be included in medical insurance. The original drugs marketed overseas are very expensive. The price of each box of 40 mg/vial may be around RMB 90,000 (the price may fluctuate due to the exchange rate). Currently, there is no generic version of Vitin-Tisotuzumab on the market. For more drug information and specific prices, please consult the medical consultant of the drug.